AbbVie Inc. $ABBV Shares Bought by Mirae Asset Global Investments Co. Ltd.

17 Apr 2026, 08:44 by Renee Jackson · The Cerbat Gem

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.3% during the fourth quarter, HoldingsChannel reports. The firm owned 826,903 shares of the company’s stock after purchasing an additional 2,702 shares during the quarter. AbbVie accounts for approximately 0.5% of Mirae Asset Global Investments Co. Ltd.’s investment portfolio, making the stock its 28th largest holding. Mirae Asset Global Investments Co. Ltd.’s holdings in AbbVie were worth $188,939,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP lifted its position in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Raymond James Financial Inc. grew its holdings in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the period. Alliancebernstein L.P. increased its stake in shares of AbbVie by 31.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock valued at $1,685,918,000 after acquiring an additional 1,758,657 shares during the last quarter. Amundi increased its stake in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares during the last quarter. Finally, Danske Bank A S purchased a new position in shares of AbbVie during the 3rd quarter worth about $279,609,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of AbbVie stock opened at $209.00 on Friday. AbbVie Inc. has a 1-year low of $168.54 and a 1-year high of $244.81. The company has a market capitalization of $369.55 billion, a PE ratio of 88.56, a P/E/G ratio of 0.74 and a beta of 0.38. The business has a 50-day moving average of $219.30 and a 200-day moving average of $223.67.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Motley Fool says ABBV is a “no‑brainer” buy on dips, highlighting its high dividend, cash flow and defensive pharma profile as reasons value/dividend investors should buy weakness. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
Positive Sentiment: AbbVie announced head‑to‑head Phase 4 psoriasis study updates — a potential near‑term clinical catalyst that could influence commercial positioning in immunology if results favor AbbVie’s therapy. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
Positive Sentiment: AbbVie kicked off a Phase 1 trial for ABBV‑295 (obesity), signalling a strategic push into the high‑growth weight‑loss market where success could materially expand future revenue streams. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
Positive Sentiment: AbbVie paid an upfront of ~$650M to RemeGen for global rights to RC148 — a sizeable bolt‑on that strengthens the company’s oncology/rare disease pipeline (near‑term cash outflow but potential long‑term value). RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
Neutral Sentiment: Evercore ISI trimmed its price target slightly ($233→$232) but kept an Outperform rating — a minor analyst tweak that maintains institutional conviction. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally
Neutral Sentiment: Sector pieces and market reports (value stock roundups; thyroid‑eye‑disease market research) include AbbVie as a key player — these reinforce investor awareness but don’t move fundamentals immediately. 1 Value Stock Worth Your Attention and 2 That Underwhelm Thyroid Eye Disease Treatment Market Research Report 2026
Negative Sentiment: Technicals are a headwind: the stock is trading below both the 50‑day and 200‑day moving averages, which can pressure short‑term sentiment and limit upside until price recovers those levels.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ABBV. Royal Bank Of Canada started coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Barclays started coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Finally, Piper Sandler boosted their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

Read Our Latest Analysis on ABBV

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Five stocks we like better than AbbVie

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).